¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"non stress test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 4
¿µ¹® tuberculin test ÇÑ±Û Æ©º£¸£Ä𸰰˻ç
¼³¸í   
  ¸¹Àº ¼­·Î ´Ù¸¥ ÇüÅÂÀÇ Æ©º£¸£Ä𸰰ú ´Ù¾çÇÑ Åõ¿©¹æ¹ý¿¡ ÀÇÇÑ ¸ðµç Á¾·ùÀÇ °áÇÙ ÇǺΰ˻ç¹ý. ÇöÀç Ç¥ÁØ ½ÃÇè¹ýÀ¸·Î µÇ¾îÀִ °¡À堽źù¼ºÀִ °Ë»ç·Î´Â PPD¸¦ Çdz»ÁÖ»çÇϴ ¹æ¹ý¸ÁÅä¿ì °Ë»çÀÌ´Ù. Çdz»ÁÖ»çÈÄ 48~72½Ã°£ ÈÄ¿¡ ÁÖ»çºÎÀ§¿¡ Á÷°æ 10mmÀÌ»óÀ¸·Î º¸À̸ç, ¸¸Á®Áö´Â È«¹Ý°ú °æÈ­°¡ ³ªÅ¸³ª¸é ¾ç¼ºÀÌ´Ù. ¼ºÀο¡°Ô´Â ÀϹÝÀûÀ¸·Î Áß°£ °­µµÀÇ Æ©º£¸£Äð¸°(5Tu)À» »ç¿ëÇϸç, ¾ç¼º¹ÝÀÀÀÌ ³ªÅ¸³ª¸é °áÇÙ±Õ¿¡ ÀÌÀü¿¡ °¨¿°µÇ¾ú°Å³ª ÇöÀç °¨¿°µÇ¾î Àִٴ ȮÁ¤Àû Áø´ÜÀÌ µÈ´Ù. À½¼º¹ÝÀÀÀº °áÇÙÀÌ ¾ø°Å³ª, ½ÉÇÑ °áÇÙ°¨¿°¿¡ ÀÇÇÑ ÇǺξ˷¹¸£±â°¡ ÀÖÀ» °æ¿ì, ¶Ç´Â ¸é¿ª¾ïÁ¦¸¦ ³ªÅ¸³»´Â º´, ¿¹¸¦ µé¸é È£ÁöŲº´À̳ª »ç¸£ÄÚÀ̵åÁõ µîÀÌ ÇÕº´µÈ °æ¿ìÀÌ´Ù.
¿µ¹® Papanicolaou smear(test) ÇÑ±Û ÆÄÆÄ´ÏÄÝ·Î µµ¸»°Ë»ç
¼³¸í   
  ÁÙ¿©¼­ ÆËµµ¸»°Ë»ç(Pap smear)À̶ó°í ºÎ¸¥´Ù. ¿©¼ºÀÇ Àڱøñ¾ÏÀÇ ¹ß»ýÀ» ¹Ì¸® ¾Ë¾Æº¸±â À§ÇØ ½ÃÇàÇϴ °Ë»ç¹ýÀ¸·Î ¹Ì±¹¿¡¼­´Â ÀÌ ¹æ¹ýÀ¸·Î ÇöÀç Àڱøñ¾Ï¹ß»ý¿¡ ÀÇÇÑ »ç¸Á·üÀ» ÇöÀúÈ÷ ³·Ãß°í ÀÖ´Ù. ¹æ¹ýÀº »êºÎÀΰú¿¡¼­ ½ÃÇàÇϸç, ¿©¼ºÀÇ Àڱøñ¿¡¼­ ¼¼Æ÷¸¦ °¡Á®´Ù°¡ µµ¸»ÇÏ¿© Çö¹Ì°æÀ¸·Î °Ë»çÇÑ´Ù. ¿äÁîÀ½¿¡ ¿Í¼­´Â Àڱøñ»Ó ¾Æ´Ï¶ó È£Èí±â³ª ºñ´¢±â µî ºÐºñ¹°À» µµ¸»ÇÏ¿© ÆÄÆÄ´ÏÄݷΠ¿°»öÀ» ÇÏ¿© °Ë»çÇϴ °Íµµ ¿©±â¿¡ Æ÷ÇԵȴÙ.
  
  (±×¸² P-3).
¿µ¹® glucose tolerance test ÇÑ±Û Æ÷µµ´ç°ßµõ°Ë»ç
¼³¸í   
  Æ÷µµ´ç°ßµõ °Ë»ç¶õ ´ç´¢º´ÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â °Ë»ç·Î ´çÀ» Ã¼³»¿¡ Åõ¿©ÇÏ°í ½Ã°£ º°·Î Ç÷¾×À» Ã¤ÃëÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Àç¾î¼­ °íÇ÷´ç ¿©ºÎ¸¦ Á¶»çÇϴ °Ë»çÀÌ´Ù. ÁַΠ°æ±¸Æ÷µµ´ç°ßµõ°Ë»ç(oral glucose tolerance test)¸¦ ¸¹ÀÌ Çϴµ¥ À̰ÍÀº 10~16½Ã°£ÀÇ ±Ý½Ä ÈÄ¿¡ Ã¤Ç÷À» Çѹø Çѵڿ¡ µµ´ç 75gÀ» 250~300mLÀÇ ¹°¿¡ ³ì¿© 5ºÐ¿¡ °ÉÃļ­ ¸¶½Ã°Ô ÇÏ°í ¸Å½Ã°£ º°·Î Ã¤Ç÷À» ÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Ã½Å©ÇÑ´Ù. °øº¹½Ã¿¡ Á¤¸Æ¿¡¼­ Ã¤Ç÷ÇÏ¿© ÃøÁ¤ÇÑ Ç÷´çÀÌ 140mg/dLÀÌ»óÀ̰ųª Æ÷µµ´ç°ßµõ °Ë»ç 2½Ã°£ÈÄÀÇ Ç÷´çÀÌ 200mg/dLÀÌ»óÀÏ °æ¿ì¿¡´Â ´ç´¢º´À¸·Î Áø´ÜÀ» ÇÑ´Ù. ±×·¯³ª ÀÌ °Ë»ç¸¦ ½Ç½ÃÇÒ °æ¿ì¿¡ ÁÖÀÇÇØ¾ß ÇÒ Á¡Àº °Ë»çÀü 3Àϰ£ ÇÏ·ç¿¡ 150gÀÌ»óÀǠź¼öÈ­¹°À» ¼·ÃëÇØ¾ß ÇѴٴ °Í°ú °Ë»çµµÁß¿¡ ¿îµ¿, Èí¿¬ µîÀ» ÇÏÁö ¾Ê¾Æ¾ß ÇѴٴ °ÍÀÌ´Ù. 
¿µ¹® blood test ÇÑ±Û Ç÷¾×°Ë»ç
¼³¸í   
  Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇϴ °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é À̵頼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • aptitude test
    Àû¼º°Ë»ç
  • articulation test
    ¹ßÀ½°Ë»ç
  • association test
    ¿¬»ó°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • occult blood test
    ÀáÇ÷°Ë»ç
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
  • osmotic fragility test
    »ïÅõ¾ÐÃë¾à¼º°Ë»ç, »ïÅõ¾Ð¿©¸²¼º°Ë»ç
  • Pap test
    (¢¡Papanicolaou test) ÆÄÆÄ´ÏÄݷΰ˻ç
  • Papanicolaou test
    ÆÄÆÄ´ÏÄݷΰ˻ç
  • patch test
    ÇǺÎÁ¢Ã˰˻ç, øÆ÷°Ë»ç
  • paternity test
    Ä£ÀÚ°¨Á¤
  • pilot test
    ¿¹ºñ°Ë»ç
  • pin prick test
    ¹Ù´Ãµû²û°Ë»ç, ¹Ù´ÃÅë°¢°Ë»ç
  • postcoital test
    ¼º±³Èİ˻ç
  • pregnancy test
    ÀӽŰ˻ç
  • provocation test
    À¯¹ß°Ë»ç, À¯¹ß¹ÝÀÀ°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
  • quantitative test
    Á¤·®°Ë»ç
  • reduction test
    ȯ¿ø½ÃÇè
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • absorption test
    Èí¼ö½ÃÇè, Èí¼ö°Ë»ç
  • acceptance test
    Àμö°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
  • air conduction test
    ±âµµ°Ë»ç, °ø±âÀüµµ°Ë»ç
  • alkali denaturation test
    ¾ËÄ®¸®º¯¼º°Ë»ç
  • alternate cover test
    ±³´ë°¡¸²°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Chopras test
    ¼îÇÁ¶ó°Ë»ç.
  • Congo red test
    Äá°íÀû½ÃÇè.»ýÈ­Äá°í·¹µå½ÃÇè.
  • Continuous Performance Test
    Áö¼Ó¼öÇà °Ë»ç
  • Coombs consumption test
    Äñ½º¼Ò¸ð°Ë»ç
  • Cosyntropin stimulation test
    ÄÚ½ÅÆ®·ÎÇÉ ÀڱؽÃÇè
  • Cuboni s test
    Äíº¸´Ï½ÃÇè.
  • Cytronbergs test
    ½ÃÆ®·Ðº£¸£Å©½ÃÇè.
  • DAT =>direct antiglobulin test
    Á÷Á¢ Çױ۷κҸ°½ÃÇè
  • DDST=Denver developmental screening test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç
  • DNase test
    DNA ºÐÇØÈ¿¼Ò½ÃÇè
  • DST=dexamethasone supression test
    µ¦»ç¸ÞŸ¼Õ ¾ïÁ¦°Ë»ç
  • Dehydration test
    Å»¼ö°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • non-leukemic
    ºñ¹éÇ÷º´(ÞªÛÜúìÜ»)(¼º)ÀÇ
  • non-leukemic lymphoblast
    ºñ¹éÇ÷º´(¼º)¸²ÇÁ¸ð±¸(×úÇÁٽϹ)
  • non-lysosomal proteinase
    ºñ¸®¼Ò¼Ø¼º ´Ü¹éºÐÇØÈ¿¼Ò(¡­àõ Ó±ÛÜÝÂú°ý£áÈ)
  • non-neoplastic
    ºñ½Å»ý¹°¼º(ÞªãæßæÚªàõ)
  • non-neurogenic neurogenic bladder
    ºñ½Å°æÀμº½Å°æÀμº¹æ±¤
  • non-neuropathic psychologic bladder
    ºñ½Å°æº´Áõ¼º ½É¸®Àû ¹æ±¤
  • non-nucleated erythrocyte
    ¹«ÇÙ(Ùíú·)ÀûÇ÷±¸
  • non-organ specific or systemic
    Àå±â ºñƯÀ̼ºÀÇ, Àü½ÅÀûÀÇ
  • non-parametric
  • non-parasitic object
    ºñ±â»ý¼º(ÞªÐößæàõ)¹°Ã¼
  • non-projectile vomiting
    ºñºÐ»ç¼º±¸Åä
  • non-protein nitrogenous compound
    ºñ´Ü¹é(Áú)Áú¼ÒÈ­ÇÕ¹°
  • non-specific
    ºñƯÀ̼ºÀÇ
  • non-suppressible insulin-like activity
    ºñ¾ïÁ¦Àν¶¸°¾ç Ȱ¼º
  • non-suppurative otitis media
    ºñÈ­³ó¼ºÁßÀÌ¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • insulin stimulating test
    Àν¶¸° ÀڱؽÃÇè(í©Ð½ãËúÐ)
  • insulin tolerance test
    Àν¶¸° ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • interfacial test
    °è¸é°Ë»ç(Í£ØüËþÞÛ)
  • ketostix test
    ÄÉÅ佺ƽ°Ë»ç(ËþÞÛ)
  • lactose tolerance test
    "¶ôÅ佺 ºÎÇϰ˻ç(ݶùÃËþÞÛ), ¶ôÅ佺³»¼º°Ë»ç(Ò±àõËþÞÛ)"
  • liver function test
    °£±â´É °Ë»ç(ÊÜÐüÒöËþÞÛ)
  • load test
    ºÎÇϰ˻ç(ݶùÃËþÞÛ)
  • Luria-Delbrueck fluctuation test
    ·ç¸®¾Æ-µ¨ºê¸¯ ¿äµ¿½ÃÇè(èôÔÑãËúÐ)
  • metyrapone test
    ¸ÞƼ¶óÆù°Ë»ç(ËþÞÛ)
  • Molisch test
    ¸ô¸®½¬ ½ÃÇè(ãËúÐ)
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
  • patch test
    ÆÐÄ¡½ÃÇè(ãËúÐ)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
LFT latex fixation test; latex flocculation test; left fronto-transverse [fetal position]; liver functio...
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
SAT saliva alcohol test; satellite; serum antitrypsin; single-agent chemotherapy; slide agglutination te...
SRT sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
E test Epsilometer test
ASD Acute Stress Disorder
CMS Chronic mild stress
CSR Combat stress reactions
CFS Conditioned fear stress
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-malignant
    ºñ¾Ç¼º
  • non-neoplastic
    ºñ½Å»ý¹°¼º
  • non-nociceptive A delta C primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive cell
    ºñÄ§ÇØ ¼ö¿ë¼º ¼¼Æ÷, ºñÀ¯ÇØ ¼ö¿ë¼º ¼¼Æ÷
  • non-nociceptive myelinated afferent
    ºñÄ§ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • non-noxious cutaneous stimulation system
    ºñÀ¯Çؼº ÇǺΠÀڱذè
  • non-odontogenic
    ºñÄ¡¼º
  • non-opiate
    ºñ¾ÆÆí¼º
  • non-painful cutaneous stimulation system
    ºñÅëÁõ¼º Àڱذè
  • non-painful masticatory muscle hypertrophy
    ºñÅëÁõ¼º ÀúÀÛ±Ù ºñ´ë
  • non-patient
    ºñȯÀÚ
  • non-peptide transmitter
    ºñÆéƼµå Àü´Þ ¹°Áú
  • non-precious metal alloy base metal alloy
    ºñ±Í±Ý¼Ó ÇÕ±Ý
    Co-CrÀ̳ª Ni-Cr ÇÕ±Ý µî È­ÇÐÀûÀ¸·Î ºÒ¾ÈÁ¤ÇÑ
  • non-problematic TMJ clicking
    ¹®Á¦°¡ ¾ø´Â ÃøµÎÇϾǰüÀý ÀâÀ½
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
auctorum non Not of authors.
(09 Jan 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
chromosomal proteins, non-histone Nucleoproteins which in contrast to histones are acid insoluble. They are involved in chromosomal functions; e.g. They bind selectively to DNA, stimulate transcription resulting in tissue-specific RNA synthesis and undergo specific changes in response to various hormones or phytomitogens.
(12 Dec 1998)
prescriptions, non-drug Written directions for the preparation, administration, or application of a non-drug remedy. This includes prescriptions for corrective lenses, self-help and orthopedic devices, and physical therapy and rehabilitation measures.
(12 Dec 1998)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
histiocytosis, non-langerhans-cell Group of disorders which feature accumulations of active histiocytes and lymphocytes, but where the histiocytes are not langerhans cells. The group includes haemophagocytic lymphohistiocytosis, infection-associated haemophagocytic syndrome, sinus histiocytosis, xanthogranuloma, reticulohistiocytoma, juvenile xanthoma, xanthoma disseminatum, as well as the lipid storage diseases (sea-blue histiocyte syndrome and niemann-pick disease).
(12 Dec 1998)
nodular non-X histiocytosis A rare recurring generalised eruption in adults of flesh coloured or erythematous papules remaining localised to the skin and consisting of dermal nodules of mononuclear histiocytes that do not stain for lipid.
Synonym: nodular non-X histiocytosis.
(05 Mar 2000)
non-arcon articulator An articulator with the equivalent condylar guides attached to the lower member and the hinge axis to the upper member.
(05 Mar 2000)
non compos mentis Not of sound mind; mentally incapable of managing one's affairs.
Origin: L. Non, not, + compos, participating, competent, + mens, gen. Mentis, mind
(05 Mar 2000)
non-direct transmission <epidemiology> A mode of transmission that differs in some mysterious way from indirect transmission.
(05 Dec 1998)
non-ego <psychology> The union of being and relation as distinguished from, and contrasted with, the ego. See Ego.
Origin: L, not I.
Source: Websters Dictionary
(01 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
  • herd test
    ¼Ò¶¼ÀÇ °Ë»ç(ƯÁ¤ Á¥¼Ò¶¼ÀÇ À¯Áö¹æ ÇÔÀ¯À² °Ë»ç)
  • inkblot test
    RORSCHACH TEST
  • intelligence test
    ±â´É°Ë»ç
  • intradermal test
    (ÀÇ)Çdz»(¸é¿ª)Å×½ºÆ®
  • mantoux test
    ¸ÁÅõ ¹ÝÀÀ (°áÇÙÀ̳ª °¨¿°ÀÇ °Ë»ç¿ë)
  • means test
    (¿µ) ¼öÀÔ (ÀÚ»ê) Á¶»ç(»ýȰ º¸È£µîÀ» ¹Þ´Â ÀÚÀÇ)
  • mental test
    Áö´É °Ë»ç
  • multiple choice test
    ¼±´ÙÇü Å×½ºÆ®
  • nuclear test
    ÇÙ½ÇÇè
  • nuclear test ban treaty
    ÇÙ½ÇÇè ±ÝÁö Á¶¾à
  • patch test
    øÆ÷ ½ÃÇè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á